Related Experiment Video
Updated: Jan 15, 2026

04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
29.5K
Use of Esketamine NS in Treatment-Resistant Depression/Gambling Disorder Comorbidity: A Case Report
Matteo Lupi1, Alessandro Carano1, Tiziano Acciavatti2
1NHS, Mental Health Department, AST Ascoli Piceno, Marche matteo826@yahoo.it.
Journal of Clinical Psychopharmacology
|October 14, 2025
Abstract
No abstract available in PubMed .
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
823
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
823
Electroconvulsive Therapy
891
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
891
Psychosis: Goals of Pharmacotherapy
469
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
469

